Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Use of long-term constitutive expression of VEGF for therapeutic angiogenesis may be limited by the growth of abnormal blood vessels and hemangiomas. We investigated the relationship between VEGF dosage and the morphology and function of newly formed blood vessels by implanting retrovirally transduced myoblasts that constitutively express VEGF164 into muscles of adult mice. Reducing VEGF dosage by decreasing the total number of VEGF myoblasts implanted did not prevent vascular abnormalities. However, when clonal populations of myoblasts homogeneously expressing different levels of VEGF were implanted, a threshold between normal and aberrant angiogenesis was found. Clonal myoblasts that expressed low to medium levels of VEGF induced growth of stable, pericyte-coated capillaries of uniform size that were not leaky and became VEGF independent, as shown by treatment with the potent VEGF blocker VEGF-TrapR1R2. In contrast, clones that expressed high levels of VEGF induced hemangiomas. Remarkably, when different clonal populations were mixed, even a small proportion of cells with high production of VEGF was sufficient to cause hemangioma growth. These results show for the first time to our knowledge that the key determinant of whether VEGF-induced angiogenesis is normal or aberrant is the microenvironmental amount of growth factor secreted, rather than the overall dose. Long-term continuous delivery of VEGF, when maintained below a threshold microenvironmental level, can lead to normal angiogenesis without other exogenous growth factors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kieckens, L., Gertsenstein, M., Fahrig, M., Vandenhoeck, A., Harpal, K., Eberhardt, C., et al. (1996) · Nature · doi:10.1038/380435a0 · Cited by 4,117
Vascular-specific growth factors and blood vessel formation
Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J., & Holash, J. (2000) · Nature · doi:10.1038/35025215 · Cited by 3,699
Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
Ferrara, N., Carver-Moore, K., Chen, H., Dowd, M., Lu, L., O'Shea, K. S., Powell-Braxton, L., Hillan, K. J., & Moore, M. W. (1996) · Nature · doi:10.1038/380439a0 · Cited by 3,628
Polymeric system for dual growth factor delivery
Richardson, T. P., Peters, M. C., Ennett, A. B., & Mooney, D. J. (2001) · Nature Biotechnology · doi:10.1038/nbt1101-1029 · Cited by 1,752
VEGF-Trap: A VEGF blocker with potent antitumor effects
Holash, J., Davis, S., Papadopoulos, N., Croll, S. D., Ho, L., Russell, M., Boland, P., Leidich, R., Hylton, D., Burova, E., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172398299 · Cited by 1,691 · cited 2×
“VEGF-TrapR1R2, which consists of portions of the extracellular domains of VEGFR-1 and VEGFR-2 coupled to human Fc, is a soluble form of VEGF receptors that can be used to deplete active VEGF in vivo (30).”
BackgroundLutolf, M. P., Lauer-Fields, J. L., Schmoekel, H. G., Metters, A. T., Weber, F. E., Fields, G. B., & Hubbell, J. A. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0737381100 · Cited by 1,508 · cited 1×
“These represent a diverse class of biomaterials that allow the homogeneous delivery of one or even two factors simultaneously (47, 48).”
BackgroundLeakage-Resistant Blood Vessels in Mice Transgenically Overexpressing Angiopoietin-1
Thurston, G., Suri, C., Smith, K., McClain, J., Sato, T. N., Yancopoulos, G. D., & McDonald, D. M. (1999) · Science · doi:10.1126/science.286.5449.2511 · Cited by 1,359
Self-citationAngiopoietin-1 protects the adult vasculature against plasma leakage
Thurston, G., Rudge, J. S., Ioffe, E., Zhou, H., Ross, L., Croll, S. D., Glazer, N., Holash, J., McDonald, D. M., & Yancopoulos, G. D. (2000) · Nature Medicine · doi:10.1038/74725 · Cited by 1,297
Self-citationHouck, K. A., Leung, D. W., Rowland, A. M., Winer, J., & Ferrara, N. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)35712-0 · Cited by 1,127 · cited 1×
“The VEGF164 isoform delivered binds heparin (41, 42) and is likely to localize around each VEGF-producing cell.”
Background
Cited by
Lutolf, M. P., & Hubbell, J. A. (2005) · Nature Biotechnology · doi:10.1038/nbt1055 · Cited by 4,551
A TALE nuclease architecture for efficient genome editing
Miller, J. C., Tan, S., Qiao, G., Barlow, K. A., Wang, J., Xia, D. F., Meng, X., Paschon, D. E., Leung, E., Hinkley, S. J., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1755 · Cited by 2,098
Why are tumour blood vessels abnormal and why is it important to know?
Nagy, J. A., Chang, S.-H., Dvorak, A. M., & Dvorak, H. F. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604929 · Cited by 611
“One mechanism by which MVs evolve into capillaries involves intraluminal bridging, a process that was originally discovered in tumour vessels (Nagy et al, 1995), but which has since been found to occur in the angiogenesis induced by Ad-VEGF-A164 (Pettersson et al, 2000) and healing wounds (Ren et al, 2002), and after…”
BackgroundInfluentialType H blood vessels in bone modeling and remodeling
Peng, Y., Wu, S., Li, Y., & Crane, J. L. (2020) · Theranostics · doi:10.7150/thno.34126 · Cited by 599
Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation
Baluk, P., Tammela, T., Ator, E., Lyubynska, N., Achen, M. G., Hicklin, D. J., Jeltsch, M., Petrova, T. V., Pytowski, B., Stacker, S. A., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200522037 · Cited by 597
Self-citationRen, X., Feng, Y., Guo, J., Wang, H., Li, Q., Yang, J., Hao, X., Lv, J., Ma, N., & Li, W. (2015) · Chemical Society Reviews · doi:10.1039/c4cs00483c · Cited by 573
Zhang, J., Muri, J., Fitzgerald, G., Gorski, T., Gianni-Barrera, R., Masschelein, E., D’Hulst, G., Gilardoni, P., Turiel, G., Fan, Z., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.05.004 · Cited by 533
Self-citationEndothelial von Willebrand factor regulates angiogenesis
Starke, R. D., Ferraro, F., Paschalaki, K. E., Dryden, N. H., McKinnon, T. A. J., Sutton, R. E., Payne, E. M., Haskard, D. O., Hughes, A. D., Cutler, D. F., et al. (2011) · Blood · doi:10.1182/blood-2010-01-264507 · Cited by 512
Vascular Endothelial Growth Factors
Ylä-Herttuala, S., Rissanen, T. T., Vajanto, I., & Hartikainen, J. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.09.053 · Cited by 480
Role of Angiogenesis in Cardiovascular Disease: A Critical Appraisal
Khurana, R., Simons, M., Martin, J. F., & Zachary, I. C. (2005) · Circulation · doi:10.1161/circulationaha.105.535294 · Cited by 451
Molecular Mediators of Angiogenesis
Ucuzian, A. A., Gassman, A. A., East, A. T., & Greisler, H. P. (2010) · Journal of Burn Care & Research · doi:10.1097/bcr.0b013e3181c7ed82 · Cited by 446
It Takes Two to Tango: Coupling of Angiogenesis and Osteogenesis for Bone Regeneration
Grosso, A., Burger, M. G., Lunger, A., Schaefer, D. J., Banfi, A., & Di Maggio, N. (2017) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2017.00068 · Cited by 445
Self-citationPathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin
Phung, T. L., Ziv, K., Dabydeen, D., Eyiah-Mensah, G., Riveros, M., Perruzzi, C., Sun, J., Monahan-Earley, R. A., Shiojima, I., Nagy, J. A., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.07.003 · Cited by 438
Controlled Growth Factor Delivery for Tissue Engineering
Tayalia, P., & Mooney, D. J. (2009) · Advanced Materials · doi:10.1002/adma.200900241 · Cited by 430
Angiogenesis is associated with blood-brain barrier permeability in temporal lobe epilepsy
Rigau, V., Morin, M., Rousset, M.-C., de Bock, F., Lebrun, A., Coubes, P., Picot, M.-C., Baldy-Moulinier, M., Bockaert, J., Crespel, A., et al. (2007) · Brain · doi:10.1093/brain/awm118 · Cited by 429
Tallawi, M., Rosellini, E., Barbani, N., Cascone, M. G., Rai, R., Saint-Pierre, G., & Boccaccini, A. R. (2015) · Journal of The Royal Society Interface · doi:10.1098/rsif.2015.0254 · Cited by 366
Role of angiogenesis in bone repair
Saran, U., Gemini Piperni, S., & Chatterjee, S. (2014) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2014.07.006 · Cited by 362
Hsieh, P. C. H. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25878 · Cited by 357
Ehrbar, M., Djonov, V. G., Schnell, C., Tschanz, S. A., Martiny-Baron, G., Schenk, U., Wood, J., Burri, P. H., Hubbell, J. A., & Zisch, A. H. (2004) · Circulation Research · doi:10.1161/01.res.0000126411.29641.08 · Cited by 357
The Pivotal Role of Vascularization in Tissue Engineering
Auger, F. A., Gibot, L., & Lacroix, D. (2013) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071812-152428 · Cited by 334
Spaide, R. F. (2015) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2015.04.012 · Cited by 313
Extracellular regulation of VEGF: Isoforms, proteolysis, and vascular patterning
Vempati, P., Popel, A. S., & Mac Gabhann, F. (2014) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2013.11.002 · Cited by 313
Adipose Vascular Endothelial Growth Factor Regulates Metabolic Homeostasis through Angiogenesis
Sung, H.-K., Doh, K.-O., Son, J. E., Park, J. G., Bae, Y., Choi, S., Nelson, S. M. L., Cowling, R., Nagy, K., Michael, I. P., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2012.12.010 · Cited by 303
Hypoxia affects mesenchymal stromal cell osteogenic differentiation and angiogenic factor expression
Potier, E., Ferreira, E., Andriamanalijaona, R., Pujol, J.-P., Oudina, K., Logeart-Avramoglou, D., & Petite, H. (2007) · Bone · doi:10.1016/j.bone.2006.11.024 · Cited by 294
Dose-dependent response of FGF-2 for lymphangiogenesis
Chang, L. K., Garcia-Cardeña, G., Farnebo, F., Fannon, M., Chen, E. J., Butterfield, C., Moses, M. A., Mulligan, R. C., Folkman, J., & Kaipainen, A. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404272101 · Cited by 276
Helm, C.-L. E., Fleury, M. E., Zisch, A. H., Boschetti, F., & Swartz, M. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503681102 · Cited by 269
Kinnaird, T., Stabile, E., Burnett, M. S., & Epstein, S. E. (2004) · Circulation Research · doi:10.1161/01.res.0000137878.26174.66 · Cited by 265
The Effect of Matrix Density on the Regulation of 3-D Capillary Morphogenesis
Ghajar, C. M., Chen, X., Harris, J. W., Suresh, V., Hughes, C. C. W., Jeon, N. L., Putnam, A. J., & George, S. C. (2008) · Biophysical Journal · doi:10.1529/biophysj.107.120774 · Cited by 264
Engineering Bacteria‐Activated Multifunctionalized Hydrogel for Promoting Diabetic Wound Healing
Lu, Y., Li, H., Wang, J., Yao, M., Peng, Y., Liu, T., Li, Z., Luo, G., & Deng, J. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202105749 · Cited by 262
VEGF may contribute to macrophage recruitment and M2 polarization in the decidua
Wheeler, K. C., Jena, M. K., Pradhan, B. S., Nayak, N., Das, S., Hsu, C.-D., Wheeler, D. S., Chen, K., & Nayak, N. R. (2018) · PLOS ONE · doi:10.1371/journal.pone.0191040 · Cited by 258
Matrices and scaffolds for DNA delivery in tissue engineering
De Laporte, L., & Shea, L. D. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.03.017 · Cited by 258
Dual-delivery of VEGF and PDGF by double-layered electrospun membranes for blood vessel regeneration
Zhang, H., Jia, X., Han, F., Zhao, J., Zhao, Y., Fan, Y., & Yuan, X. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2012.12.005 · Cited by 250
Hypoxia Triggers the Intravasation of Clustered Circulating Tumor Cells
Donato, C., Kunz, L., Castro-Giner, F., Paasinen-Sohns, A., Strittmatter, K., Szczerba, B. M., Scherrer, R., Di Maggio, N., Heusermann, W., Biehlmaier, O., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108105 · Cited by 224
“…fat pad of NSG mice, simultaneously treated with either EphrinB2 Fc chimera protein—previously shown to activate EphB4 signaling and to ensure normal and functional angiogenesis along with elevated VEGFA levels (Groppa et al., 2018; Ozawa et al., 2004)—or Fc fragments as controls (Figure 7A).”
Self-citationWang, Y. (2004) · Brain · doi:10.1093/brain/awh325 · Cited by 221
“In analogy, a recent study has shown that local tissue concentrations of VEGF critically determine whether proper angiogenesis takes place or abnormal vasculature is formed (Ozawa et al., 2004), pointing to the importance of having the right amount of VEGF at the right place.”
The Foreign Body Response Demystified
Chandorkar, Y., K, R., & Basu, B. (2019) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.8b00252 · Cited by 201
Martino, M. M., Brkic, S., Bovo, E., Burger, M., Schaefer, D. J., Wolff, T., Gürke, L., Briquez, P. S., Larsson, H. M., Gianni-Barrera, R., et al. (2015) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2015.00045 · Cited by 185
“…that VEGF does not have an intrinsically steep dose–response curve in vivo, but rather that the dose delivered must be controlled at the microenvironmental level (Ozawa et al., 2004; Von Degenfeld et al., 2006; Misteli et al., 2010; Melly et al., 2012; Wolff et al., 2012; Mujagic et al., 2013).”
Self-citationInnate Immunity and Angiogenesis
Frantz, S., Vincent, K. A., Feron, O., & Kelly, R. A. (2005) · Circulation Research · doi:10.1161/01.res.0000153188.68898.ac · Cited by 185
DNA delivery from hyaluronic acid-collagen hydrogels via a substrate-mediated approach
Segura, T., Chung, P. H., & Shea, L. D. (2005) · Biomaterials · doi:10.1016/j.biomaterials.2004.05.007 · Cited by 163
“Ozawa CR, Banfi A, Glazer NL, Thurston G, Springer ML, Kraft PE, et al. Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis.”
BackgroundStructure and function of the interphotoreceptor matrix surrounding retinal photoreceptor cells
Ishikawa, M., Sawada, Y., & Yoshitomi, T. (2015) · Experimental Eye Research · doi:10.1016/j.exer.2015.02.017 · Cited by 153
Plasmin Modulates Vascular Endothelial Growth Factor-A-Mediated Angiogenesis during Wound Repair
Roth, D., Piekarek, M., Paulsson, M., Christ, H., Bloch, W., Krieg, T., Davidson, J. M., & Eming, S. A. (2006) · The American Journal of Pathology · doi:10.2353/ajpath.2006.050372 · Cited by 127
Jay, S. M., Shepherd, B. R., Andrejecsk, J. W., Kyriakides, T. R., Pober, J. S., & Saltzman, W. M. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.01.014 · Cited by 85
“Previous work has shown that high levels of VEGF delivery can lead to vascular regression [37] and formation of pathologic, as opposed to physiologic, vasculature [38].”
Takayama, K., Kawakami, Y., Mifune, Y., Matsumoto, T., Tang, Y., Cummins, J. H., Greco, N., Kuroda, R., Kurosaka, M., Wang, B., et al. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.03.036 · Cited by 71
The promotion of endothelial cell attachment and spreading using FNIII10 fused to VEGF-A165
Traub, S., Morgner, J., Martino, M. M., Höning, S., Swartz, M. A., Wickström, S. A., Hubbell, J. A., & Eming, S. A. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.04.050 · Cited by 42
(2025) · doi:10.1021/acs.biomac.5c00097 · Cited by 5
Metadata
- Authors
- Ozawa, C. R., Banfi, A., Glazer, N. L., Thurston, G., Springer, M. L., Kraft, P. E., McDonald, D. M., & Blau, H. M.
- Venue
- Journal of Clinical Investigation
- Published
- 2004-02-15
- Volume
- 113
- Issue
- 4
- Pages
- 516-527
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2061940955
- Cited by
- 520
- References
- 50
- FWCI
- 11.26
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.